Geron Corp. (GERN), a commercial-stage biopharmaceutical company, on Wednesday announced that it has appointed Harout Semerjian as President and Chief Executive Officer with effective August 7.
Semerjian will take over from Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Bir will remain on the Board of Directors to provide expertise and strategic guidance.
Semerjian has more than 30 years of experience and most recently served at GlycoMimetics.
The company said that the appointment comes at a critical time for the company focuses on increasing awareness and accessibility of RYTELO and progressing its late-stage pipeline, including completing the pivotal Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis.
In the pre-market trading, Geron is 8.33% higher at $1.3000 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.